Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
R-NanoBio
Wako-shi, Saitama, Japanr-nanobio.co.jp ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
R-NanoBio has developed and commercialized a platform technology enabling rapid, onsite multiplexed diagnostic testing using microarray chips. Their flagship product allows allergy screening from fingertip blood samples for 41 allergens within 30 minutes at clinics. The company is expanding the application of its platform to other disease biomarkers.
- Therapeutic areas
- ImmunologyOther
- Modalities
- Microarray biochipDiagnostic device
- Industry
- Protein Biomarker Diagnostics
Beyond the preview
Go deeper on R-NanoBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-NanoBio.